NCT00872521 · OUTCOME

Overall Survival (OS) Stratified by Protein Expression (p53).

A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma · Source last updated 2014-05-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: Not reported
Time frame: 2 years after Day 1 Cycle 1 of PAD

What was measured

Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (p53).

Analysis population: Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD. The OS was not imputed.

Groups in this outcome

Negative

Participants without p53 expression

Positive

Participants with p53 expression

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Negative	65
Positive	13

Reported measurements

Source class 1

Values in Percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Negative	90.7	Not reported	Not reported	Not reported	Not reported
Positive	92.3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
90.7
group Id
OG001
value
92.3

denoms

counts
group Id
OG000
value
65
group Id
OG001
value
13
units
Participants

description

Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (p53).

groups

description
Participants without p53 expression
id
OG000
title
Negative
description
Participants with p53 expression
id
OG001
title
Positive

param Type

NUMBER

population Description

Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD. The OS was not imputed.

reporting Status

POSTED

time Frame

2 years after Day 1 Cycle 1 of PAD

title

Overall Survival (OS) Stratified by Protein Expression (p53).

type

SECONDARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice